熱門資訊> 正文
Ambev非GAAP每股收益为0.22雷亚尔，收入为2015亿雷亚尔;重申财年指引
2026-07-30 15:48
- Ambev press release (ABEV): Q2 Non-GAAP EPS of R$0.22.
- Revenue of R$20.15B (+0.3% Y/Y).
- Consolidated volumes increased 1.4% in 2Q26.
- Normalized EBITDA grew by 8.9%, with all our business units delivering Normalized EBITDA growth. Normalized EBITDA margin increased by 80 bps, to 31.6%, supported by disciplined revenue and cost management.
- Cash flow from operating activities increased 54.5% compared to R$ 3,050.0 million in 2Q25.
- "While we remain mindful that the global geopolitical environment continues to be dynamic, we remain focused on disciplined execution and resource allocation and maintain our full-year guidance unchanged, expecting an increase of between 4.5% and 7.5% in our Brazil Beer Cash COGS/hl excluding the sale of nonAmbev products on the marketplace."
More on Ambev
- Ambev: Don't Ignore This High-Quality Beverage Leader
- Ambev: The Market Has Sobered Up Recently
- Ambev May Be Overestimated And Overvalued In 2026
- Ambev Q2 2026 Earnings Preview
- These 10 large and mega-cap U.S. consumer staples firms rank among the market's most attractively valued stocks
推薦文章
美股前瞻 | 史詩級「軋空」來襲！比特幣升破7.2萬美元；業績股齊遇冷！沃爾瑪盤前大跌逾6%，阿里、網易均跌近4%
一圖看懂 | 泡泡瑪特上半年營收171億、淨利50億均大遜預期！星星人IP逆勢暴漲580%；王寧稱計劃半年內大額回購20-50億
Moderna暴漲177%！mRNA癌症疫苗迎來「ChatGPT時刻」？16只港美標的誰會接過下一棒？
「影子股」已暴漲90%！如何在Anthropic史上最大IPO前搶跑入局？最全攻略來了
港股異動 | 全球首個mRNA癌症疫苗三期成功落地！港股醫藥股齊衝高，康希諾生物飆升49%，雲頂新耀勁升42%
資金流向顯示億萬富豪Ken Fisher旗下機構以40億美元逆勢抄底長期美債
SK海力士出手救市！擬回購並註銷約283億美元的股票
賽力斯港股上市后首虧!半年虧掉17億,狂燒70億搞研發
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
